The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family

Haematologica

Volumn 96, Issue 1, 2011, Pages 110-118

  Bade Döding, Christina ^a,b   Theodossis, Alex ^c   Gras, Stephanie ^c   Kjer Nielsen, Lars ^b   Eiz Vesper, Britta ^a   Seltsam, Axel ^d   Huyton, Trevor ^a   Rossjohn, Jamie ^c   McCluskey, James ^b   Blasczyk, Rainer ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Institute Springe   (Germany)

Author keywords

HLA B*41; Micropolymorphism; Peptide motif; X ray crystallography

Indexed keywords

GLUTAMIC ACID; HLA B ANTIGEN; LEUCINE; PROLINE; VALINE;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTIGEN STRUCTURE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONTROLLED STUDY; CRYSTAL STRUCTURE; EMBRYO; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; MULTIGENE FAMILY; PEPTIDE ANALYSIS; PROTEIN MOTIF;

EPITOPES, T-LYMPHOCYTE; HLA-B ANTIGENS; HUMANS; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78650992438     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.030924     Document Type: Article

References (56)

1. Chelvanayagam G. A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities. Immunogenetics. 1996;45(1):15-26.
2. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol. 2008;8 (8):607-18.
3. Kim Y, Sidney J, Pinilla C, Sette A, Peters B. Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior. BMC Bioinformatics. 2009;10:394.
4. Zhao Y, Gran B, Pinilla C, Markovic-Plese S, Hemmer B, Tzou A, et al. Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands. J Immunol. 2001;167(4):2130-41.
5. Zhang C, Bickis MG, Wu FX, Kusalik AJ. Optimally-connected hidden Markov models for predicting MHC-binding peptides. J Bioinform Comput Biol. 2006;4(5):959-80.
6. Mamitsuka H. Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models. Proteins. 1998;33(4):460-74.
7. Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 2009;10:296.
8. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351(6324):290-6.
9. Bade-Doeding C, Eiz-Vesper B, Figueiredo C, Seltsam A, Elsner HA, Blasczyk R. Peptide-binding motif of HLA-A*6603. Immunogenetics. 2005;56(10):769-72.
10. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3-4):213-9.
11. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008;36(Web Server issue):W509-12.
12. Reche PA, Glutting JP, Zhang H, Reinherz EL. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics. 2004;56(6):405-19.
13. DeLuca DS, Blasczyk R. Implementing the modular MHC model for predicting peptide binding. Methods Mol Biol. 2007;409: 261-71.
14. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152(1):163-75.
15. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol. 2006;27(1):11-6.
16. Tynan FE, Burrows SR, Buckle AM, Clements CS, Borg NA, Miles JJ, et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class Ibound peptide. Nat Immunol. 2005;6(11): 1114-22.
17. Green KJ, Miles JJ, Tellam J, van Zuylen WJ, Connolly G, Burrows SR. Potent T cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length. Eur J Immunol. 2004;34(9):2510-9.
18. Bade-Doeding C, Elsner HA, Eiz-Vesper B, Seltsam A, Holtkamp U, Blasczyk R. A single amino-acid polymorphism in pocket A of HLA-A*6602 alters the auxiliary anchors compared with HLA-A*6601 ligands. Immunogenetics. 2004;56(2):83-8.
19. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell. 1978;14(1):9-20.
20. Brodsky FM, Parham P, Barnstable CJ, Crumpton MJ, Bodmer WF. Monoclonal antibodies for analysis of the HLA system. Immunol Rev. 1979;47:3-61.
21. Hirosawa M, Hoshida M, Ishikawa M, Toya T. MASCOT: multiple alignment system for protein sequences based on threeway dynamic programming. Comput Appl Biosci. 1993;9(2):161-7.
22. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215(3):403-10.
23. Macdonald W, Williams DS, Clements CS, Gorman JJ, Kjer-Nielsen L, Brooks AG, et al. Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex. FEBS Lett. 2002;527(1-3):27-32.
24. Wynn KK, Fulton Z, Cooper L, Silins SL, Gras S, Archbold JK, et al. Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection. Blood. 2008;111 (8):4283-92.
25. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Cryst. 1993;26:795-800.
26. Storoni LC, McCoy AJ, Read RJ. Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 3):432-8.
27. Zernich D, Purcell AW, Macdonald WA, Kjer-Nielsen L, Ely LK, Laham N, et al. Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. J Exp Med. 2004;200(1):13-24.
28. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53(Pt 3):240-55.
29. Afonine PV, Grosse-Kunstleve RW, Adams PD. A robust bulk-solvent correction and anisotropic scaling procedure. Acta Crystallogr D Biol Crystallogr. 2005;61(Pt 7):850-5.
30. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron-density maps and the location of errors in these models. Acta Crystallogr A. 1991;47 (Pt 2):110-9.
31. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(Pt 12 Pt 1):2126-32.
32. Lamzin VS, Wilson KS. Automated refinement of protein models. Acta Crystallogr D Biol Crystallogr. 1993;49(Pt 1):129-47.
33. Merritt EA. Expanding the model: anisotropic displacement parameters in protein structure refinement. Acta Crystallogr D Biol Crystallogr. 1999;55(Pt 6):1109-17.
34. Vaguine AA, Richelle J, Wodak SJ. SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr D Biol Crystallogr. 1999;55(Pt 1):191-205.
35. Torsion angle dynamics: reduced variable conformational sampling enhances crystallographic structure refinement. Proteins. 1994;19(4):277-90.
36. Brunger AT. Version 1.2 of the Crystallography and NMR system. Nat Protoc. 2007;2(11):2728-33.
37. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007;35(Web Server issue): W375-83.
38. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33(Web Server issue):W368-71.
39. Bade-Doeding C, DeLuca DS, Seltsam A, Blasczyk R, Eiz-Vesper B. Amino acid 95 causes strong alteration of peptide position Pomega in HLA-B*41 variants. Immunogenetics. 2007;59(4):253-9.
40. Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nat Struct Biol. 2003;10(12):980.
41. Probst-Kepper M, Hecht HJ, Herrmann H, Janke V, Ocklenburg F, Klempnauer J, et al. Conformational restraints and flexibility of 14-meric peptides in complex with HLAB* 3501. J Immunol. 2004;173(9): 5610-6.
42. Miles JJ, Borg NA, Brennan RM, Tynan FE, Kjer-Nielsen L, Silins SL, et al. TCR alpha genes direct MHC restriction in the potent human T cell response to a class I-bound viral epitope. J Immunol. 2006;177(10): 6804-14.
43. Tynan FE, Reid HH, Kjer-Nielsen L, Miles JJ, Wilce MC, Kostenko L, et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol. 2007;8(3):268-76.
44. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983;22(12):2577-637.
45. Theodossis A, Guillonneau C, Welland A, Ely LK, Clements CS, Williamson NA, et al. Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition. Proc Natl Acad Sci USA. 2010;107 (12):5534-9.
46. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006;34(Web Server issue): W116-8.
47. Kumar S, Nussinov R. Relationship between ion pair geometries and electrostatic strengths in proteins. Biophys J. 2002;83(3):1595-612.
48. Smith KD, Epperson DF, Lutz CT. Alloreactive cytotoxic T-lymphocytedefined HLA-B7 subtypes differ in peptide antigen presentation. Immunogenetics. 1996;43(1-2):27-37.
49. Ghei M, Stroncek DF, Provenzano M. Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides. J Transl Med. 2005;3:23.
50. Pietersz GA, Li W, Apostolopoulos V. A 16- mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway. Vaccine. 2001;19(11-12):1397-405.
51. Matsumura S, Kita H, He XS, Ansari AA, Lian ZX, Van De Water J, et al. Comprehensive mapping of HLA-A0201- restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis. Hepatology. 2002;36(5):1125-34.
52. Slezak SL, Bettinotti M, Selleri S, Adams S, Marincola FM, Stroncek DF. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med. 2007;5:17.
53. Bell MJ, Burrows JM, Brennan R, Miles JJ, Tellam J, McCluskey J, et al. The peptide length specificity of some HLA class I alleles is very broad and includes peptides of up to 25 amino acids in length. Mol Immunol. 2009;46(8-9):1911-7.
54. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol. 1991;219(2):277-319.
55. Bailey S. The CCP4 suite: programs for protein crystallography. Acta Cryst. 1994;50(Pt 5):760-3.
56. Lee B, Richards FM. The interpretation of protein structures: estimation of static accessibility. J Mol Biol. 1971;55(3):379-400.